Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 2/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1116701 | 0.92 | CPA1 (0.47) | CPA1ALDH1A1CYP2C19LMNAMME | |
| SCHEMBL14042757 | 0.92 | CPA1 (0.47) | CPA1ALDH1A1CYP2C19LMNAMME | |
| SCHEMBL1409156 | 0.87 | CPA1 (0.61) | CPA1ALDH1A1LMNA | |
| SCHEMBL4311209 | 0.86 | CPA1 (0.54) | CPA1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4311206 | 0.86 | CPA1 (0.54) | CPA1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12199163 | 0.82 | CPA1 (0.47) | CPA1ALDH1A1CYP2C19LMNAMME | |
| SCHEMBL5245067 | 0.78 | ZDHHC7 (0.43) | CPA1ALDH1A1CYP2C19LMNA | |
| SCHEMBL5163506 | 0.78 | CPA1 (0.50) | CPA1ALDH1A1CYP2C19LMNASMN1; SMN2 | |
| SCHEMBL1427009 | 0.78 | CPA1 (0.50) | CPA1ALDH1A1CYP2C19LMNASMN1; SMN2 | |
| SCHEMBL13567330 | 0.76 | CPA1 (0.52) | CPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312335-B2 | Asymmetric Michael and Aldol additions using bifunctional cinchona-alkaloid-based catalysts | BRANDEIS UNIVERSITY (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1758899-A1 | ASYMMETRIC MICHAEL AND ALDOL ADDITION USING BIFUNCTIONAL CINCHONA-ALKALOID-BASED CATALYSTS | Brandeis University (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20060014956-A1 | Asymmetric Michael and Aldol additions using bifunctional cinchona-alkaloid-based catalysts | BRANDEIS UNIVERSITY | 2006-01-19 | — | — | US | disclosed |
| WO-2005121137-A1 | ASYMMETRIC MICHAEL AND ALDOL ADDITION USING BIFUNCTIONAL CINCHONA-ALKALOID-BASED CATALYSTS | BRANDEIS UNIVERSITY (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014956-A1 | Asymmetric Michael and Aldol additions using bifunctional cinchona-alkaloid-based catalysts | ALDH3A1, NQO1, DERA | CPA1 475/4885ALDH1A1 13/4885CYP2C19 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.